Treatment in Early Relapse Multiple Myeloma: Takeaways from EHA 2024

In part 1 of our interview with Leland Metheny, MD, he explained how a new triple-target chimeric antigen receptor (CAR) T-cell therapy works in multiple myeloma.

The complete response letter (CRL) was issued based on a pre-approval inspection at a third-party fill/finish manufacturer.

To continue the response they experienced with a first autologous stem‐cell transplant (ASCT) for their multiple myeloma, patients in this analysis received a second ASCT, with French investigators evaluating their outcomes.

Patients who have comorbid relapsed/refractory multiple myeloma (RRMM) and advanced chronic kidney disease (CKD) are often excluded from clinical trials, leaving treatment gaps for these high-risk patients.

Relapsed/refractory multiple myeloma (RRMM) remains an incurable hematologic cancer, often resulting in patients treated with several classes of medications—particularly older patients.

Daratumumab/hyaluronidase-fihj plus bortezomib, lenalidomide, and dexamethasone is now approved by the FDA to treat newly diagnosed multiple myeloma (MM) in patients eligible for autologous stem cell transplant.